Evidence map›Paper›PMID 40806269›Full record

ArticleInternational journal of molecular sciences2025

Automated Segmentation and Morphometric Analysis of Thioflavin-S-Stained Amyloid Deposits in Alzheimer's Disease Brains and Age-Matched Controls Using Weakly Supervised Deep Learning.

Gábor Barczánfalvi, Tibor Nyári, József Tolnai, László Tiszlavicz, Balázs Gulyás, Karoly Gulya

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gábor BarczánfalviDepartment of Cell Biology and Molecular Medicine, University of Szeged, 6720 Szeged, Hungary.
Tibor NyáriDepartment of Medical Physics and Informatics, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0001-8900-6641
József TolnaiDepartment of Medical Physics and Informatics, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0002-7648-764X
László TiszlaviczDepartment of Pathology, University of Szeged, 6725 Szeged, Hungary.
Balázs GulyásDepartment of Clinical Neuroscience, Karolinska Institute, 171 77 Stockholm, Sweden.ORCID 0000-0001-9295-2460
Karoly GulyaDepartment of Cell Biology and Molecular Medicine, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0001-6864-4150

Funding

Ministry of National Resources GINOP 2.3.2-15-2016-00030 and 2.3.2-15-2016-00034
6 · The paper itself

Abstract

Alzheimer's disease (AD) involves the accumulation of amyloid-β (Aβ) plaques, whose quantification plays a central role in understanding disease progression. Automated segmentation of Aβ deposits in histopathological micrographs enables large-scale analyses but is hindered by the high cost of detailed pixel-level annotations. Weakly supervised learning offers a promising alternative by leveraging coarse or indirect labels to reduce the annotation burden. We evaluated a weakly supervised approach to segment and analyze thioflavin-S-positive parenchymal amyloid pathology in AD and age-matched brains. Our pipeline integrates three key components, each designed to operate under weak supervision. First, robust preprocessing (including retrospective multi-image illumination correction and gradient-based background estimation) was applied to enhance image fidelity and support training, as models rely more on image features. Second, class activation maps (CAMs), generated by a compact deep classifier SqueezeNet, were used to identify, and coarsely localize amyloid-rich parenchymal regions from patch-wise image labels, serving as spatial priors for subsequent refinement without requiring dense pixel-level annotations. Third, a patch-based convolutional neural network, U-Net, was trained on synthetic data generated from micrographs based on CAM-derived pseudo-labels via an extensive object-level augmentation strategy, enabling refined whole-image semantic segmentation and generalization across diverse spatial configurations. To ensure robustness and unbiased evaluation, we assessed the segmentation performance of the entire framework using patient-wise group k-fold cross-validation, explicitly modeling generalization across unseen individuals, critical in clinical scenarios. Despite relying on weak labels, the integrated pipeline achieved strong segmentation performance with an average Dice similarity coefficient (≈0.763) and Jaccard index (≈0.639), widely accepted metrics for assessing segmentation quality in medical image analysis. The resulting segmentations were also visually coherent, demonstrating that weakly supervised segmentation is a viable alternative in histopathology, where acquiring dense annotations is prohibitively labor-intensive and time-consuming. Subsequent morphometric analyses on automatically segmented Aβ deposits revealed size-, structural complexity-, and global geometry-related differences across brain regions and cognitive status. These findings confirm that deposit architecture exhibits region-specific patterns and reflects underlying neurodegenerative processes, thereby highlighting the biological relevance and practical applicability of the proposed image-processing pipeline for morphometric analysis.

Indexed as

Alzheimer DiseaseBenzothiazolesBrainDeep LearningImage Processing, Computer-AssistedPlaque, AmyloidAgedAged, 80 and overAmyloid beta-PeptidesCase-Control StudiesFemaleHumansMaleAmyloid beta-PeptidesBenzothiazolesthioflavin TAlzheimer’s diseaseamyloid plaquesclass activation mappingmicroscopic morphometrythioflavin-Sweakly supervised semantic segmentation

Identifiers

PMID40806269
PMCPMC12346360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.